» Articles » PMID: 34036745

Weight Changes After Antiretroviral Therapy Initiation in CoRIS (Spain): a Prospective Multicentre Cohort Study

Abstract

Introduction: Weight gain after starting antiretroviral therapy (ART) is a major problem that can increase morbidity. Our main objective was to evaluate the effects of initial ART on weight change in a large prospective cohort of HIV-positive individuals.

Methods: This was a prospective cohort study of 13,198 subjects included in the Spanish HIV Research Network (CoRIS) between January 2004 and November 2018. We included subjects who started triple ART and achieved HIV RNA suppression within 48 weeks. We fitted linear mixed models adjusted for potential confounders to compare longitudinal changes in weight. We used Cox proportional-hazard models to compare treatment groups' times to transition to a higher body mass index (BMI) category.

Results: We analysed data from a total of 1631 individuals resulting in 14,965 persons/years and 14,085 observations. Individuals retained in the final multivariable model were representative of the overall cohort. NNRTI-based first-line ART was associated with a lower average weight gain compared to PI- (+0.7 kg per year, 95% CI 0.5 to 1.0, p < 0.001) and INSTI-based (+0.9 kg per year, 95% CI 0.7 to 1.1, p < 0.001) regimens. Individuals starting ART with TAF+FTC had greater weight gain than those receiving TDF+FTC (+0.8 kg per year, 95% CI 0.3 to 1.4, p = 0.004). Women and black persons presented a greater weight gain than men and non-black individuals. Differences in weight trajectories were driven mainly by changes during the first year of ART. The NNRTI group was less likely to transition from normal weight to overweight than the PI (aHR 1.48, 95% CI 1.18 to 1.85) and INSTI groups (aHR 1.30, 95% CI 1.03 to 1.64). PIs but not INSTIs were associated with a higher rate of overweight-to-obesity shift (aHR 2.17, 95% CI 1.27 to 3.72). No differences were found among INSTIs in the transition to a higher BMI category.

Conclusions: INSTI- and PI-based first-line ARTs are associated with greater weight gain compared to NNRTI-based ART. Within the NRTIs, TAF+FTC was most strongly associated with weight gain. This heterogeneous effect of ART on body weight could affect the long-term risk of some non-communicable diseases.

Citing Articles

Optimizing cardiometabolic risk in people living with human immunodeficiency virus: A deep dive into an important risk enhancer.

Kobe E, Thakkar A, Matai S, Akkaya E, Pagidipati N, McGarrah R Am J Prev Cardiol. 2024; 20:100888.

PMID: 39552706 PMC: 11566711. DOI: 10.1016/j.ajpc.2024.100888.


Cardiometabolic health in people with HIV: expert consensus review.

Batterham R, Bedimo R, Diaz R, Guaraldi G, Lo J, Martinez E J Antimicrob Chemother. 2024; 79(6):1218-1233.

PMID: 38656584 PMC: 11144490. DOI: 10.1093/jac/dkae116.


Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study.

Sawry S, Ayalew K, Maimela G, Briggs-Hagen M, van Wyk-Heath M, Mthethwa S HIV Med. 2024; 25(7):826-839.

PMID: 38520085 PMC: 11263972. DOI: 10.1111/hiv.13638.


The Impact of Contemporary Antiretroviral Drugs on Atherosclerosis and Its Complications in People Living With HIV: A Systematic Review.

Vemulapalli A, Elias A, Yerramsetti M, Olanisa O, Jain P, Khan Q Cureus. 2023; 15(10):e47730.

PMID: 38021858 PMC: 10676193. DOI: 10.7759/cureus.47730.


Effect of dolutegravir-based first-line antiretroviral therapy on weight and body mass index among adult people living with HIV on follow up at health facilities in Hawassa city administration, Southern Ethiopia: a retrospective cohort study.

Hirigo A, Yilma D, Astatkie A, Debebe Z Ann Med. 2023; 55(2):2242250.

PMID: 37531412 PMC: 10399476. DOI: 10.1080/07853890.2023.2242250.


References
1.
Kumar S, Samaras K . The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018; 9:705. PMC: 6277792. DOI: 10.3389/fendo.2018.00705. View

2.
Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S . Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381(9):816-826. DOI: 10.1056/NEJMoa1904340. View

3.
Griesel R, Maartens G, Chirehwa M, Sokhela S, Akpomiemie G, Moorhouse M . CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz. Clin Infect Dis. 2020; 73(11):e3902-e3909. PMC: 8653639. DOI: 10.1093/cid/ciaa1073. View

4.
Gomez M, Seybold U, Roider J, Harter G, Bogner J . A retrospective analysis of weight changes in HIV-positive patients switching from a tenofovir disoproxil fumarate (TDF)- to a tenofovir alafenamide fumarate (TAF)-containing treatment regimen in one German university hospital in 2015-2017. Infection. 2018; 47(1):95-102. PMC: 7384998. DOI: 10.1007/s15010-018-1227-0. View

5.
Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A . Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS. 2008; 22(12):925-30. PMC: 2707924. DOI: 10.1089/apc.2008.0082. View